Therapeutic Proteins And Oral Vaccines Market is estimated to be valued at USD 288.6 Mn in 2025 and is expected to reach USD 497.8 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.
Analysts’ Views on Global Therapeutic Proteins and Oral Vaccines Market:
Increasing adoption of technology by market players, growing inorganic growth strategies by market players, and increasing product launches will drive the growth of the global therapeutic proteins and oral vaccines market. For instance, in January 2022, Amgen Inc., a biotechnology company, and Generate Biomedicines, a drug generation company, announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
Figure 1. Global Therapeutic Proteins and Oral Vaccines Market Share (%), By Drug Class, 2025
To learn more about this report, Request sample copy
Global Therapeutic Proteins and Oral Vaccines Market– Drivers
Rising Number of Clinical Trials by Major Companies
Figure 2. Global Therapeutic Proteins and Oral Vaccines Market Share (%), By Region, 2025
To learn more about this report, Request sample copy
Global Therapeutic Proteins and Oral Vaccines Market- Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global therapeutic proteins and oral vaccines market over the forecast period. North America is estimated to hold 33.5% of the market share in 2025. The North America therapeutic proteins and oral vaccines market is expected to witness significant growth in the coming years, driven by the increasing growth strategies by market players such as signing distribution agreement in the region. For instance, in November 2021, Pfizer Inc. announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID (PF-07321332; ritonavir), subject to regulatory authorization from the U.S. Food and Drug Administration (FDA). Under the terms of the agreement, the U.S. government will acquire 10 million treatment courses to be delivered by Pfizer beginning later this year and concluding in 2022.
Therapeutic Proteins And Oral Vaccines Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 288.6 Mn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 8.1% | 2032 Value Projection: | USD 497.8 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson and Johnson, Merck & Co.Inc., Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd., and Lumen Bioscience, Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Therapeutic Proteins and Oral Vaccines Market– Impact of Coronavirus (COVID-19) Pandemic
Global Therapeutic Proteins and Oral Vaccines Market Segmentation:
The therapeutic proteins and oral vaccines market report is segmented by drug class, by application, by distribution channel, and by region.
Global Therapeutic Proteins and Oral Vaccines Market- Cross Sectional Analysis:
Key players operating in the market are focused on inorganic growth strategies, such as acquisition, which is expected to boost the therapeutic proteins and oral vaccines market in North America region. For instance, in November 2022, Merck & Co., Inc., and Imago BioSciences, Inc., a biotechnology company, announced that the companies had entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago Biosciences, Inc., for US$36.00 per share in cash for an approximate total equity value of US$1.35 billion. Imago Biosciences, Inc., is a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Imago’s lead candidate bomedemstat (IMG-7289), an investigational orally available lysine-specific demethylase 1 (LSD1) inhibitor, is currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia (ET), myelofibrosis (MF), and polycythemia vera (PV), in addition to other indications.
Global Therapeutic Proteins and Oral Vaccines Market: Key Developments
Global Therapeutic Proteins and Oral Vaccines Market: Key Trends
Global Therapeutic Proteins and Oral Vaccines Market: Restraint
Lower Availability and Affordability of Therapeutic Proteins in Lower Income Countries
Global Therapeutic Proteins and Oral Vaccines Market - Key Players
Major players operating in the global therapeutic proteins and oral vaccines market include Abbott Laboratories, Amgen, Inc., Biogen, Inc., Eli Lilly and Company, Eli Lilly and Company, Johnson and Johnson, Merck & Co.Inc., Novo Nordisk A/S, Pfizer, Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Emergent Biosolutions Inc., TransAlgae, MigVax Ltd., and Lumen Bioscience, Inc.
Definition: Therapeutic proteins are one of the prime option of biologicals as per their clinical uses. Protein therapeutics are used extensively to treat various diseases like cancer, AIDS etc. Therapeutic proteins can be used to replace a protein that is abnormal or deficient in a particular disease. A protein is a large molecule comprised of a long chain of amino acids that is folded into a three-dimensional shape. The specific amino acid sequence and 3-D shape determines the biological function of the protein.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our ClientsUS Reciprocal Tax Impact Analysis On Therapeutic Proteins And Oral Vaccines Market
Stay updated on tariff changes with expert insights and timely information